Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development

Bibliography

• Goldman JM, Melo JV. Chronic myeloid leukemia–advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-64
   PubMed Web of Science ®Google Scholar
• Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 2004;5:33-44
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Hochhaus A, Baccarani M; European LeukemiaNet. Chronic myeloid leukaemia. Lancet 2007;370:342-50
   PubMed Web of Science ®Google Scholar
• Faderl S, Talpaz M, Estrov Z, Kantarjian H. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999;131:207-19
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1 positive chronic myeloid leukaemia. Blood 2009;113:1619-30
   PubMed Web of Science ®Google Scholar
• Melo JV, Deininger MW. Biology of chronic myelogenous leukaemia-signaling pathways of initiation and transformation. Hematol Oncol Clin North Am 2004;18:545-68
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Faderl S, O'Brien S, Chronic myelogenous leukaemia: a review and update of therapeutic strategies. Cancer 2003;98:437-57
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med 2001;344:1031-7
   PubMed Web of Science ®Google Scholar
• Johnson JR, Bross P, Cohen M, Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase. Clin Cancer Res 2003;9:1972-9
   PubMed Web of Science ®Google Scholar
• Deininger MW, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukaemia. Blood 2005;105:2640-53
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Goldman JM, International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). Blood 2008;112: abstract 186
   Google Scholar
• Deininger MW, O'Brien SG, Guilhot F, International randomized study of interferon vs STI571(IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114:1126
   Web of Science ®Google Scholar
• Breccia M, Alimena G. Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem. Cardiovasc Hematol Disord Drug Targets 2009;9:21-8
   PubMedGoogle Scholar
• Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018-29
   PubMed Web of Science ®Google Scholar
• Apperley JF. Part II: management of resistance to imatinib in chronic myeloid leukemia. Lancet Oncol 2007;8:1116-28
   PubMed Web of Science ®Google Scholar
• Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett 2007;249:121-32
   PubMed Web of Science ®Google Scholar
• Milojkovic D, Apperley JF. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukaemia. Clin Cancer Res 2009;15:7519-27
   PubMed Web of Science ®Google Scholar
• Irvine DA, Heaney NB, Holyoake TL. Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors-A synthesis of clinical and laboratory data. Blood Rev 2009;24:1-9
   Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S, Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance and mutations in the ATP phosphate-binding loop (p-loop) are associated with a poor prognosis. Blood 2003;102:276-83
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Jones D, Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukaemia treated with imatinib mesylate. Leukemia 2006;20:1767-73
   PubMed Web of Science ®Google Scholar
• Soverini S, Colarossi S, Gnani A, Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006;12:7374-9
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Corm S, Le QH, Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukaemia patients: a retrospective analysis fron the French intergroup of CML. Leukemia 2006;20:1061-6
   PubMed Web of Science ®Google Scholar
• Sherbenou DW, Wong MJ, Humayun A, Mutations of the BCR-ABL kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia 2007;21:489-93
   PubMed Web of Science ®Google Scholar
• Khorashad JS, de Lavallade H, Apperley JF, Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukaemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008;26:4806-13
   PubMed Web of Science ®Google Scholar
• Keam SJ. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. BioDrugs 2008;22:59-69
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes J, Kantarjian H. Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. Expert Opin Investig Drugs 2007;16:679-87
   PubMed Web of Science ®Google Scholar
• Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukaemia and Philadelphia chromosome positive acute lymphoblastic leukaemia. Clin Ther 2007;29:2289-308
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes J, Kantarjian H. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol 2009;4:3-10
   PubMed Web of Science ®Google Scholar
• Olivieri A, Manzione L. Dasatinib: a new step in molecular target therapy. Ann Oncol 2007;18(Suppl 6):vi42-46
   PubMedGoogle Scholar
• Giles FJ, O'Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009;23:1698-707
   PubMed Web of Science ®Google Scholar
• O'Hare T, Eide CA, Deininger MW. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin Investig Drugs 2008;17:865-78
   PubMed Web of Science ®Google Scholar
• Shah NP. Dasatinib. Drugs Today (Barc) 2007;43:5-12
   PubMed Web of Science ®Google Scholar
• Brave M, Goodman V, Kaminskas E, Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008;14:352-9
   PubMed Web of Science ®Google Scholar
• Pavlù J, Marin D. Dasatinib and chronic myeloid leukaemia: two-year follow-up in eight clinical trials. Clin Lymphoma Myeloma 2009;9:417-24
   PubMedGoogle Scholar
• Hochhaus A, Kantarjian H, Baccarani M, Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukaemia after failure of imatinib therapy. Blood 2007;109:2303-9
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Deininger M, Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008;22:1200-6
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Lévy V, Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115:3935-43
   PubMedGoogle Scholar
• Apperley JF, Cortes JE, Kim DW, Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A Trial. J Clin Oncol 2009;27:3472-9
   PubMed Web of Science ®Google Scholar
• Cortes J, Kim DW, Raffoux E, Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008;22:2176-83
   PubMed Web of Science ®Google Scholar
• Shah NP, Kantarjian HM, Kim DW, Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-12
   PubMed Web of Science ®Google Scholar
• Saglio G, Kantarjian H, Hochhaus A, Dasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with chronic myeloid leukemia in blast phase (CML-BP): 2-year data from CA180-035. Blood 2008;112:3226
   Google Scholar
• Ocheni S, Iwanski GB, Schafhausen P, Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. Leuk Lymphoma 2009;50:551-8
   PubMed Web of Science ®Google Scholar
• Kelly K, Swords R, Mahalingam D, Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol 2009;4(2):99-105
   PubMed Web of Science ®Google Scholar
• Porkka K, Khoury HJ, Paquette R, Dasatinib 100 mg once daily (QD) maintains long-term efficacy and minimizes the occurrence of pleural effusion: an analysis of 24-month data in patients with resistance, suboptimal response, or intolerance to imatinib (CA180-034). Blood 2008;112:3242
   PubMedGoogle Scholar
• Porkka K, Khoury HJ, Paquette RL, Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010;116:377-86
   PubMed Web of Science ®Google Scholar
• Cortes J, Joned D, O'Brien S, Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010;28:398-404
   PubMed Web of Science ®Google Scholar
• Zwaan CM, Rizzari C, van der Velden VHJ, Dasatinib in children and adolescents with relapsed or refractory leukemia: interim results of the CA180-018 phase I study from the ITCC consortium. Blood 2008;112:3241
   Google Scholar
• Quintás-Cardama A, Kantarjian H, O'brien S, Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-14
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Punnialingam S, Milojkovic D, Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 2008;141:745-47
   PubMed Web of Science ®Google Scholar
• Mustjoki S, Ekblom M, Arstila TP, Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398-405
   PubMed Web of Science ®Google Scholar
• Mustjoki S, Kreutzman A, Dix C, Large granular lymphocyte (LGL) expansions comprising oligiclonal T cell or NK cell populations in dasatinib treated patients are associated with HLA-A 0201, CMV reactivation and enhanced anti-leukemic control. Blood 2009;114: abstract 1123
   Web of Science ®Google Scholar
• Valent J, Schiffer CA. Prevalence of large granular lymphocyte proliferation in chronic myeloid leukemia (CML) patients treated with dasatinib. Blood 2009;114: abstract 1111
   PubMed Web of Science ®Google Scholar
• Russo Rossi A, Ricco A, Carluccio P, T/NK lymphocytosis in CML Ph+ patients during dasatinib therapy. Blood 2009;114: abstract 3279
   Google Scholar
• Breccia M, Latagliata R, Stagno F, Comorbidities influence compliance and development of pleural effusions in elderly chronic myeloid leukemia (CML) patients treated with dasatinib. Haematologica 2009;94: s4-abstract 100
   PubMedGoogle Scholar
• la Rosee P, Leitner A, Martiat P, Weekend drug holiday of dasatinib in CML patients not tolerating standard dosing regimens. Reducing toxicity with maintained disease control. Blood 2009;114:1119
   Google Scholar